Short answer
Idexx Laboratories (IDXX) filed its Q1 2026 10-Q quarterly report on May 5, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $1.1B (up 14.3% year over year) with net income of $278M.
Q1 2026 key financials · XBRL
- Revenue
- $1.1B
- +14.3% YoY
- Net income
- $278M
- +14.7% YoY
- Operating margin
- 31.8%
- Gross margin
- 63.4%
- EPS (diluted)
- $3.47
- +17.2% YoY
Source: XBRL data from the Idexx Laboratories (IDXX) Q1 2026 10-Q on SEC EDGAR. USD.
Idexx Laboratories Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Outlook risks: geopolitical instability, tariffs, inflation, severe weather, and supply-chain challenges
- Management disclaims obligation to update forward-looking statements
Risk Factors
- Share repurchases: 604,571 shares bought during Q1 2026 at average prices of $644.46 and $593.52
- Repurchase authorization: 3,134,370 shares remaining under the 78 million-share program
- Tax compliance: 16,771 shares surrendered for employee withholding taxes
- Capital allocation: 1% excise tax applied to open-market repurchases
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Idexx Laboratories quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.